TABLE 2.

Combination between detectable/undetectable CD26+LSC and detectable/undetectable BCR::ABL1 in relapsed/non-relapsed patients at the time of TKI discontinuation. LSCs: leukemia stem cells; TFR: treatment-free remission.

	CD26+LSCs detectable	CD26+LSCs undetectable	CD26+LSCs detectable	CD26+LSCs undetectable
	BCR::ABL1 detectable	BCR::ABL1 undetectable	BCR::ABL1 undetectable	BCR::ABL1 detectable
Patients (n = 109)	25/109 (22.9%)	21/109 (19.3%)	36/109 (33.0%)	27/109 (24.7%)
TFR LOSS (n = 38)	11/38 (29.0%)	8/38 (21.0%)	12/38 (31.6%)	7/38 (18.4%)
TFR SUSTAINED (n = 71)	14/71 (19.7%)	13/71 (18.3%)	24/71 (33.8%)	20/71 (28.2%)